Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸»ÃÊÇü °£³»´ã°ü¾ÏÀÇ ¼ö¼ú ÈÄ ¿¹ÈÄ¿¡ °üÇÑ °íÂû Prognostic Factors in Resectable Peripheral Cholangiocarcinoma

´ëÇѼÒÈ­±âÇÐȸÁö 2000³â 36±Ç 5È£ p.686 ~ 694
¼Ò¼Ó »ó¼¼Á¤º¸
À̱ÔÅÃ/Kyu Taek Lee ÀÌÁ¾±Õ/ÀÌ»ó¼ö/½É»ó±º/ÀÌÁØÇõ/ÀÌdz·Ä/±èÀçÁØ/°í±¤Ã¶/¹é½Â¿î/¼Õżº/ÀÌÁ¾Ã¶/ÃÖ±Ô¿Ï/·ù±¤Çö/¹Úö±Ù/ÃÖ¼ºÈ£/¿©±Ôµ¿/Jong Kyun Lee/Sang Soo Lee/1Sang Goon Shim/Joon Hyoek Lee/Poong Lyul Rhee/Jae Jun Kim/Kwang Chul Koh/Seung Woon Paik/Tae Sung Sohn/Jong Chul Rhee/Kyoo

Abstract

kabstract :
- ¿ä¾à -
¸ñÀû : ¸»ÃÊÇü °£³»´ã°ü¾ÏÀº ¿ø¹ß¼º °£¾ÏÀÇ 5-10£¥¸¦ Â÷ÁöÇÏ¸ç ±ÙÄ¡Àû ÀýÁ¦À²ÀÌ ³·¾Æ¼­ ¿¹
ÈÄ°¡ ºÒ·®ÇÑ ¾Ï¿¡ ¼ÓÇÑ´Ù. ¼ö¼ú ÈÄ »ýÁ¸À²À» ¿¹ÃøÇÏ´Â ÀÎÀڵ鿡 ´ëÇÑ ¸î¸î º¸°í°¡ ÀÖÀ¸³ª
¾ÆÁ÷±îÁö ÀÌ°ßÀÌ ÀÖ´Â »óÅÂÀÌ´Ù. º» ¿¬±¸´Â ¸»ÃÊÇü °£³»´ã°ü¾ÏÀÇ ¼ö¼úÈÄ »ýÁ¸À²¿¡ ¿µÇâÀ»
¹ÌÄ¡´Â ¸»ÃÊÇü °£³»´ã°ü¾ÏÀÇ ¼ö¼ú ÈÄ »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÓ»óÀû, º´¸®ÇÐÀû ÀÎÀÚµéÀ»
ºÐ¼®ÇÏ¿© ¿¹Èĸ¦ ¿¹ÃøÇÏ´Â µ¥ µµ¿òÀ» ¹ÞÀ» ¼ö ÀÖ´ÂÁö¸¦ ¾Ë¾Æº¸±â À§Çؼ­ ½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1994³â 9¿ùºÎÅÍ 1999³â 9¿ù±îÁö »ï¼º¼­¿ïº´¿ø¿¡¼­ °³º¹¼úÀ» ½ÃÇà¹ÞÀº 29¿¡
ÀÇ ¸»ÃÊÇü °£³»´ã°ü¾Ï ȯÀÚµéÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ȯÀÚµéÀÇ ÀÓ»óÀû Ư¡À» ¾Ë¾Æº¸°í, ±ÙÄ¡Àû
ÀýÁ¦¼úÀ» ½ÃÇà¹ÞÀº 19¿¹¿¡¼­ »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿ä¼Ò·Î ¿¬·É, ¼ºº°, CEA, CA 19-9,
À°¾ÈÀû ÇüÅÂ, Á¶Á÷ÇÐÀû ºÐÈ­µµ, °£³» À§¼ºº´º¯ À¯¹«, Á¾¾çÀÇ Å©±â, ÀýÁ¦¸é ħÀ± À¯¹«, ¸²ÇÁ°ü
¹× Ç÷°ü ħÀ±À¯¹«, ½Å°æ ħÀ± À¯¹«, ±¹¼Ò ¸²ÇÁÀý ÀüÀÌ À¯¹«, °£ÇǸ· ħÀ± À¯¹«, °£°æº¯ µ¿¹Ý
µîÀ» ´ë»óÀ¸·Î Kaplan-Meier¹ýÀ¸·Î ´©Àû»ýÁ¸À²À» ±¸ÇÏ°í, °¢ ÀÎÀÚµéÀÌ »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿µ
ÇâÀ» ´Ùº¯·® ¹× ´Ùº¯·®ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù.
°á°ú : ³»¿ø ´ç½Ã Áõ»óÀº »óº¹ºÎ µ¿Åë ¹× ºÒÆí°¨ÀÌ 15¿¹(51.7£¥)·Î °¡Àå ¸¹¾Ò°í, °£Á¾±«·Î
³»¿øÇÑ °æ¿ì°¡ 8¿¹(27.6£¥)¿´´Ù. ÀýÁ¦±º¿¡¼­ Áß¾Ó»ýÁ¸±â°£Àº 17.6°³¿ùÀÌ°í(6.6-37.3°³¿ù), 1³â,
2³â, 3³â ´©Àû »ýÁ¸À²Àº °¢°¢ 51.4£¥, 45.0£¥, 28.1£¥¿´°í, ºñÀýÁ¦±ºÀÇ Áß¾Ó »ýÁ¸±â°£Àº 4.1°³
¿ù(2.3-10.7°³¿ù)ÀÌ°í, 1³â »ýÁ¸À²Àº 0£¥¿´´Ù.(p£¼0.01). ±ÙÄ¡Àû ÀýÁ¦¼öÀ» ½ÃÇà¹ÞÀº ȯÀÚµéÀÇ
´Ùº¯·®ºÐ¼®¿¡¼­ À¯ÀÇÇÑ ¿¹ÈÄÀÎÀڷδ µÎ°¡Áö·Î Á¾¾çÀÇ Å©±â¿Í ½Å°æ ħÀ± À¯¹«¿´´Âµ¥, Á¾¾ç
ÀÇ Å©±â°¡ 5cm ¹Ì¸¸±º¿¡¼­ 1³â, 2³â, 3³â »ýÁ¸À²ÀÌ 83.3£¥, 66.7£¥, 44.4£¥¿´°í, 5cm ÀÌ»ó±º
¿¡¼­ 1³â, 2³â »ýÁ¸À²Àº 30.0£¥, 30.0£¥·Î Åë°èÀû À¯ÀǼºÀ» º¸¿´´Ù(p£¼0.05). ½Å°æħÀ±ÀÌ ¾ø´Â
±º¿¡¼­ 1³â, 2³â, 3³â »ýÁ¸À²Àº 63.6£¥, 55.6£¥, 34.7£¥¿´°í, ½Å°æ ħÀ±ÀÌ ÀÖ´Â ±ºÀº 1³â »ýÁ¸
À²ÀÌ 0£¥¿´´Ù(p£¼0.05). ÇÑÆí ¿¬·É µîÀÇ ´Ù¸¥ ÀÎÀÚµéÀº ¿¹ÈÄÀÎÀڷμ­ À¯ÀǼºÀÌ ¾ø¾ú´Ù.
°á·Ð : ¸»ÃÊÇü °£³»´ã°ü¾ÏÀº Àû±ØÀûÀÎ ¼ö¼úÀû ÀýÁ¦°¡ »ýÁ¸À²ÀÇ Çâ»ó¿¡ ±â¿©ÇÏ¿´°í, ¼ö¼ú ÈÄ
»ýÁ¸À²À» ¿¹ÃøÇÏ´Â ÀÎÀڷμ­ Á¾¾çÀÇ Å©±â¿Í ½Å°æ ħÀ± À¯¹«µîÀ» °í·ÁÇÒ ¼ö ÀÖÀ¸³ª, ÇâÈÄ º¸
´Ù ¸¹Àº ȯÀÚµéÀ» ´ë»óÀ¸·Î ÇÑ ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.
#ÃÊ·Ï#
-Abstract-
Background/Aims: Prognostic factors related to the postoperative survival of patients
with peripheral carcinoma (PCC) are not well documented. The purpose of this study
was to evaluated the clinical and pathologic factors that might influence the
postoperative survival of patients with PCC.
Methods: Twenty-nine patients with PCC underwent laparotomy between September
1994 and September 1999. Fourteen clinicopathologic factors influencing postoperative
survival were analyze patients who underwent hepatic resection (resection group). Ten
patients had unresectable advanced tumor (unresectable group).
Results : In the resection group, the overall 1-, 2-, and 3-year survival in the
unresectable group was 4.1 months and no patient lived longer than 1 year. In
univariate survival analysis, tumor size and perineural mvasion were correlated
significantly with overall survival. The survival of patients who underwent resection
with positive margin was significantly longer than that of the unresectable group.
Conclusions: An aggressive surgical approach provides the best chance for long-term
survival of patients with PCC. Tumor size and perineural invasion may be considered as
prognostic factors for postoperative survival, but a large, long-term study is needed.

Å°¿öµå

¸»ÃÊÇü °£³»´ã°ü¾Ï; °£ÀýÁ¦; ¿¹ÈÄÀÎÀÚ; Peripheral cholangiocarcinoma; Hepatic resection; Prognosis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS